Gapping up
In reaction to earnings/guidance:
- PSO +7.9%, CNXC +3.4%, MS +2.9%, BAC +2.8%, ASML +2.2%, FAST +2.1%, BHP +2%, CFG +1.8%, PG +1.1%, IBKR +0.8%, JBHT +0.7%, .
Other news:
- ZGNX +66% (to be acquired by UCB for $26.00 per share in cash)
- SOFI +17% (received regulatory approval to become Bank Holding Company through proposed acquisition of Golden Pacific Bancorp)
- GMDA +10.4% (provides update on omidubicel BLA submission; Full BLA submission on track for first half of 2022)
- BKKT +9.5% (announced a partnership with regulated digital assets institution Nexo to custody cryptocurrency assets in the Bakkt Warehouse)
- LPTX +8.5% (to present data from DisTinGuish study of DKN-01 at ASCO)
- TGNA +6.7% (Standard General and Apollo [APO] nearing deal for co according to NY Post)
- IBRX +5% (announced interim results from QUILT 88 trial)
- OCX +4.1% (announced development and co-marketing agreement for two distributed IVD assays on Thermo Fisher's [TMO] Ion Torrent Genexus System)
- VMEO +2.9% (reported performance metrics for December)
- DNA +2.8% (announces acquisition of Project Beacon COVID-19)
- BTCM +2.4% (provides operational and business updates)
- PWP +2.2% (prices offering of 3502033 shares of common stock at $10.75 per share)
- CMRX +2.1% (announces publication of ONC201 data from Phase 2 study in neuroendocrine tumors)
- EXAS +2% (Presents Data Showing Improved Accuracy of Second-generation Cologuard Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients)
- RVNC +1.3% (received official Type A meeting minutes from the FDA regarding
- CRL for DaxibotulinumtoxinA for Injection for glabellar lines)
- MTRX +1.2% (awarded project from Chemours [CC] at West Virginia facility)
- NICE +1.2% (announced a partnership to digitally transform police case building and investigations to accelerate the pursuit of justice)
- RILY +1.1% (announced acquisition of FocalPoint Securities)
- ENLC +1% (increased quarterly distribution)
Analyst comments:
- RKT +3.1% (upgraded to Overweight from Underweight at JP Morgan)
- XM +3% (upgraded to Outperform from In-line at Evercore ISI)
- ARCO +2.8% (upgraded to Buy from Neutral at Goldman)
- BBWI +2.2% (upgraded to Conviction Buy from Buy at Goldman)
- BCC +1.6% (upgraded to Buy from Underperform at BofA Securities)
- TNDM +1.6% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ABB +1.5% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- AKAM +0.9% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)